

TREATING PATIENTS WITH ECP A TO Z – THE NORDIC APPROACH PROGRAMME

OSLO RIKSHOSPITALET, SOGNSVANNSVEIEN 20, OSLO
DEPARTMENT OF HEMATOLOGY, C3. 2ND FLOOR

This information is intended only for healthcare professionals in Europe.

DAY 1

- 12:00 – 13:00 **Lunch**
- 13:00 – 14:00 **Department and ECP set-up**
Jørn Kristiansen
- 14:00 – 15:00 **Patient Focus and Nordic Guidelines on ECP**
Ingerid Abrahamsen, MD, PhD Haematologist
- 15:00 – 16:00 **Impact of ECP treatment on Quality of Life (QoL) and Health Economic parameters in GvHD – a local assessment**
Mari Sundholm, RN ECP nurse and Alba Pons, RN ECP nurse
- 16:00 – 17:00 **Group discussion**
Jørn Kristiansen
- 17:00 – 17:30 **Wrap up and close**
- 19:00 **Dinner**

DAY 2

- 09:00 – 10:00 **ECP in Acute and Chronic GvHD – Oslo experience**
Jørn Kristiansen
- 10:00 – 11:00 **A potential role for ECP in GvHD prophylaxis – current status of an assessment**
Maryan Ali, MD, PhD candidate, Haematologist
- 11:00 – 12:00 **Managing patients – a cross-departmental effort**
Jørn Kristiansen
- 12:00 – 13:00 **Lunch**
- 13:00 – 14:00 **Group discussion**
Jørn Kristiansen
- 14:00 **Wrap up and close**

*ECP: Extracorporeal Photopheresis



Jørn Kristiansen

Head Nurse; ECP Nurse coordinator,
Oslo University Hospital, Rikshospitalet

Brought to you by the Therakos Institute

www.therakosinstitute.eu

All speakers are subject to contract.

This is a scientific programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

[Privacy policy](#) [Legal notice](#)

Learn more about Mallinckrodt Pharmaceuticals by visiting www.mallinckrodt.com

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2019 Mallinckrodt.

Item code: EU-1900020. Date of preparation: February 2019.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our Privacy Notice provides additional information.